20
Participants
Start Date
September 1, 2023
Primary Completion Date
October 1, 2026
Study Completion Date
July 30, 2038
Afamitresgene autoleucel
Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
NOT_YET_RECRUITING
Dana Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Memorial Sloan Kettering Kids, New York
RECRUITING
Children's Hospital of Philedephia, Philadelphia
RECRUITING
National Institutes of Health, Bethesda
NOT_YET_RECRUITING
Duke University School of Medicine, Durham
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
RECRUITING
University of Wisconsin Cancer Center, Madison
RECRUITING
Washington University, St Louis
RECRUITING
Stanford University, Palo Alto
NOT_YET_RECRUITING
Seattle Children's Hospital, Seattle
Lead Sponsor
Adaptimmune
INDUSTRY